What is AVTX's dilution risk score?

AVTX has a latest available DilutionScore record of 49/100, categorized as medium dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for AVTX, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for AVTX?

DilutionWatch tracks 25 SEC filing types for AVTX including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect AVTX shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For AVTX, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for AVTX tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for AVTX. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

AVTX Dilution Risk Score: 49/100 (MEDIUM)

Score Breakdown

📋 Offering Ability

80

💰 Cash Runway

0

📊 Float Risk

45

⚠️ Warrant Exposure

30

🔄 Convertible Debt

15

Dilution Forecast

☀️

Clear

No significant dilution signals

model est. 7%

📜 Warrant Exercise model 15%

• Warrant overhang: 7.5% of shares outstanding

🔔 Track AVTX — Get forecast alerts →

Market Data

Market Cap$838.42M

Shares Outstanding53.63M

Float40.18M

Cash$400.28M

Debt$15.30M

Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

Field	Current Value	Basis
DilutionScore	49/100	DilutionWatch score record
Shares Outstanding	53.63M	Verified float table or market cache
Public Float	40.18M	Verified float table or market cache
Market Cap	$838.42M	Market data cache
Cash Runway	110.7 months	DilutionWatch score inputs
Shelf Capacity	None in current score inputs	SEC-derived dilution fields
ATM Capacity	None in current score inputs	SEC-derived dilution fields
Outstanding Warrants	4.00M	SEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 4 5, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 69.3% shares (2026Q1 vs prior)

101 institutional holders · 36.04M shares

#1 FMR LLC 2.88M shares

#2 T. Rowe Price Investment Management, Inc. 2.16M shares

#3 Caligan Partners LP 1.64M shares

+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest12.39M

Days to Cover15.2

% of Float30.8%

FINRA data as of Aug 31, 2026

Insider Buy/Sell Ratio

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31

xbrl XBRL CONVERTIBLE 2024-12-31

4 INSIDER TRANSACTION 2026-04-08

4 INSIDER TRANSACTION 2026-04-03

Full SEC filing analysis available with free account →

Recent News

No recent news

Factual AVTX Dilution Snapshot

Avalo Therapeutics, Inc. (AVTX) has a DilutionScore of 49/100, rated Medium dilution risk. Score date: September 12, 2026.

Stored outstanding warrants: 4.0M.
Recent SEC activity tracked for AVTX: 4 on 2026-04-08; 4 on 2026-04-03; 4 on 2026-04-03.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.